Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMCFree Report) by 26.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,137 shares of the biotechnology company’s stock after buying an additional 653 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Blueprint Medicines were worth $158,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Pinebridge Investments L.P. acquired a new position in shares of Blueprint Medicines in the 2nd quarter valued at approximately $46,000. Lazard Asset Management LLC acquired a new stake in Blueprint Medicines in the fourth quarter valued at $57,000. Dark Forest Capital Management LP acquired a new stake in Blueprint Medicines in the first quarter valued at $63,000. Steward Partners Investment Advisory LLC raised its holdings in Blueprint Medicines by 24.9% in the first quarter. Steward Partners Investment Advisory LLC now owns 1,682 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 335 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Blueprint Medicines in the 2nd quarter valued at about $90,000.

Wall Street Analyst Weigh In

BPMC has been the topic of a number of recent analyst reports. Oppenheimer upgraded shares of Blueprint Medicines from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research note on Friday, October 27th. Stifel Nicolaus upped their price objective on Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Morgan Stanley upped their price target on Blueprint Medicines from $59.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, October 27th. Wedbush reissued an “outperform” rating and set a $97.00 price target (down from $100.00) on shares of Blueprint Medicines in a research report on Monday, January 8th. Finally, Raymond James increased their target price on shares of Blueprint Medicines from $85.00 to $100.00 and gave the stock a “strong-buy” rating in a report on Friday, December 22nd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $81.00.

Get Our Latest Research Report on Blueprint Medicines

Blueprint Medicines Trading Down 4.8 %

Blueprint Medicines stock opened at $79.53 on Thursday. Blueprint Medicines Co. has a 52-week low of $37.82 and a 52-week high of $94.00. The company has a quick ratio of 4.01, a current ratio of 4.09 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of -8.65 and a beta of 0.73. The firm has a 50-day moving average price of $81.65 and a two-hundred day moving average price of $63.20.

Insider Activity

In related news, Director Jeffrey W. Albers sold 15,000 shares of the stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $67.51, for a total value of $1,012,650.00. Following the completion of the transaction, the director now directly owns 176,050 shares of the company’s stock, valued at approximately $11,885,135.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Jeffrey W. Albers sold 25,000 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the transaction, the director now directly owns 176,050 shares of the company’s stock, valued at $14,420,255.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 15,000 shares of the firm’s stock in a transaction on Friday, November 24th. The shares were sold at an average price of $67.51, for a total value of $1,012,650.00. Following the transaction, the director now directly owns 176,050 shares in the company, valued at $11,885,135.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,799 shares of company stock valued at $3,984,561. Insiders own 3.88% of the company’s stock.

About Blueprint Medicines

(Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib.

Read More

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.